Atogepant: all 22 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With MigraineNot yet recruitingNCT07826910Phase 4
• Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingNCT07655440Phase 4
• Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyRecruitingNCT06972056Phase 4
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsRecruitingNCT06810505Phase 3
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineRecruitingNCT05711394Phase 3
• Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With MigraineEnrolling by invitationNCT05707949Phase 3
• Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic MigraineCompletedNCT05861427Phase 3Results posted
• Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With MigraineCompletedNCT05264129Phase 4Results posted
• Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic MigraineCompletedNCT05216263Phase 3Results posted
• Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic MigraineCompletedNCT04829747Phase 3Results posted
• Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.CompletedNCT04740827Phase 3Results posted
• A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic MigraineCompletedNCT04437433Phase 3Results posted
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic MigraineCompletedNCT03939312Phase 3Results posted
• Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic MigraineCompletedNCT03855137Phase 3Results posted
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic MigraineCompletedNCT03777059Phase 3Results posted
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic MigraineCompletedNCT03700320Phase 3Results posted
• Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine PreventionCompletedNCT02848326Phase 2/3Results posted
• Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive, not recruitingNCT06806293Phase 3
• Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With MigraineCompletedNCT06241313Phase 3
• Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult VolunteersCompletedNCT05892757Phase 1
• Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of MigraineCompletedNCT04818515Phase 1
• A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic MigraineCompletedNCT04686136Phase 3

← Atogepant overview